Last reviewed · How we verify

NCT04151966

Myocardial Injury Following Elective Direct Current Cardioversion for Atrial Arrhythmias

Completed Last updated 5 January 2022
What this trial tests

trial testing Blood sample collection in Cardioversion in 104 participants. Completed in 1 December 2021.

Timeline
22 July 2019
Primary endpoint
5 June 2020
1 December 2021

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment104
Start date22 July 2019
Primary completion5 June 2020
Estimated completion1 December 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Cardioversion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Researchers are trying to determine if heart injury occurs in subjects who undergo direct current cardioversion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Absence of significant myocardial injury following elective direct current cardioversion for atrial fibrillation.
    Lobo R, White RD, Donato LJ, Wockenfus AM, et al · · 2023 · cited 5× · PMID 36993913 · DOI 10.1016/j.hroo.2022.12.004

Verify or expand the search:

Other trials of Blood sample collection

Trials testing the same drug.

Other recruiting trials for Cardioversion

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04151966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing